Literature DB >> 10631720

Early gastric stump carcinoma with rhabdoid features. Case report.

F Rivera-Hueto1, J J Ríos-Martín, R Domínguez-Triano, J M Herrerías-Gutierrez.   

Abstract

Among 474 cases of gastric carcinoma studied in gastrectomy specimens from 1990 to 1996, only one (0.21%) showed positivity for vimentin. It was located on a gastric stump and, endoscopically, the tumor was classified as early gastric carcinoma type IIb + IIc. Histologically, tumor cells were extensively round to polygonal and had eosinophilic, or clear cytoplasm; the nuclei were large with conspicuous nucleoli. In some areas, the cytoplasm showed vimentin and(or cytokeratin coexpression by double immunostaining. Our results and the patient's rapid deterioration (death occurred six months after surgery) suggest that this type of tumor, although diagnosed as early carcinoma, behaved like an advanced malignancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10631720     DOI: 10.1016/S0344-0338(99)80107-1

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

1.  Malignant rhabdoid tumour in the stomach.

Authors:  Özcem Öfkeli; Aziz Bulut; Yunus Nadi Yüksek; Halil İbrahim Yıldız
Journal:  Ulus Cerrahi Derg       Date:  2013-08-30

Review 2.  Primary malignant rhabdoid tumor of the stomach, a rare case report and review of literature.

Authors:  Bita Geramizadeh; Saman Nikeghbalian; Shokouh Abolghasem-Hosseini
Journal:  J Gastrointest Cancer       Date:  2010-12

3.  Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp.

Authors:  Shogo Kawaguchi; Tetsuro Yoshimura; Hirotake Sakuraba; Taka Asari; Yohei Sawada; Yasumitsu Araki; Koji Kikuchi; Toyohito Wada; Tomomi Kusumi; Shinsaku Fukuda
Journal:  Clin J Gastroenterol       Date:  2018-02-07

4.  Mucin-secreting gastric adenocarcinoma with Rhabdoid areas.

Authors:  Sonal Sharma; Richa Gupta; Rajeev Sharma; Mrinalini Kotru
Journal:  Saudi J Gastroenterol       Date:  2010 Jan-Mar       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.